Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Profit After Tax: 2010-2025

Historic Profit After Tax for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to -$91.3 million.

  • Iovance Biotherapeutics' Profit After Tax fell 9.23% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 3.00%. This contributed to the annual value of -$372.2 million for FY2024, which is 16.18% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Profit After Tax stood at -$91.3 million, which was up 18.27% from -$111.7 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Profit After Tax ranged from a high of -$78.6 million in Q4 2024 and a low of -$116.4 million during Q4 2023.
  • In the last 3 years, Iovance Biotherapeutics' Profit After Tax had a median value of -$107.4 million in 2023 and averaged -$103.2 million.
  • Per our database at Business Quant, Iovance Biotherapeutics' Profit After Tax spiked by 32.48% in 2024 and then dropped by 14.99% in 2025.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' Profit After Tax stood at -$116.4 million in 2023, then surged by 32.48% to -$78.6 million in 2024, then dropped by 9.23% to -$91.3 million in 2025.
  • Its Profit After Tax stands at -$91.3 million for Q3 2025, versus -$111.7 million for Q2 2025 and -$116.2 million for Q1 2025.